Focus Partners Wealth
ONC

Focus Partners Wealth’s BeOne Medicines Ltd ONC Stock Holding History

Focus Partners Wealth’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$990K Buy
3,332
+836
+33% +$271K ﹤0.01% 1627
2025
Q4 		$758K Sell
2,496
-73
-3% -$23.9K ﹤0.01% 1755
2025
Q3 		$842K Buy
2,569
+1,263
+97% +$384K ﹤0.01% 1359
2025
Q2 		$316K Buy
1,306
+159
+14% +$39K ﹤0.01% 1653
2025
Q1 		$312K Sell
1,147
-106
-8% -$24.8K ﹤0.01% 1553
2024
Q4 		$231K Sell
1,253
-9,182
-88% -$1.88M ﹤0.01% 1666
2024
Q3 		$2.34M Sell
10,435
-76
-0.7% -$13.7K 0.01% 738
2024
Q2 		$1.5M Buy
10,511
+300
+3% +$46.2K 0.01% 708
2024
Q1 		$1.6M Buy
10,211
+23
+0.2% +$3.7K 0.01% 523
2023
Q4 		$1.84M Buy
+10,188
New +$1.84M 0.02% 366

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Focus Partners Wealth's ONC Position: Q1 2026 in Review

Focus Partners Wealth increased its BeOne Medicines Ltd (ONC) stake by 33% in Q1 2026, buying an estimated $271K and bringing the position to 3,332 shares worth $990K. The position accounts for ﹤0.01% of the portfolio, ranked #1627.

Focus Partners Wealth first reported a position in ONC in Q4 2023 and has held it in 10 quarters since. The position peaked at $2.34M in Q3 2024. 281 funds tracked by Wall St. Rank hold ONC as of Q1 2026.

  • Focus Partners Wealth held 3,332 shares of BeOne Medicines Ltd worth $990K as of Q1 2026.
  • Focus Partners Wealth bought 836 BeOne Medicines Ltd shares in Q1 2026, an estimated $271K.
  • BeOne Medicines Ltd made up ﹤0.01% of Focus Partners Wealth's portfolio in Q1 2026, its #1627 holding.
  • Focus Partners Wealth first reported a position in BeOne Medicines Ltd in Q4 2023 and has held it in 10 quarters since.
  • Focus Partners Wealth's BeOne Medicines Ltd position peaked at $2.34M in Q3 2024.
  • 281 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2026.

Based on Focus Partners Wealth's 13F filing for Q1 2026, filed 15 May 2026.